viewGenprex, Inc.

Genprex boosts outreach to investors with planned launch of corporate website

The new site will include presentations, stock charts, SEC filings, news and media coverage

Oncoprex symbol
Genprex will also be forging partnerships with PR firms to improve publicity efforts

Gene-therapy company Genprex Inc (NASDAQ:GNPX) is boosting its outreach efforts to investors with the launch of a corporate website in 2019 and new email alerts.

The new site will include presentations, stock charts, SEC filings, news, media coverage and tailored email newsletters.

As part of this roll-out, investors already can receive news regarding Genprex in their inboxes by signing up for the company’s communication list here.

On top of its investor relations push, Genprex will also be forging partnerships with media relations and public relations firms to get its message out.

READ: Genprex licenses additional cancer-fighting technologies from University of Texas

“We’re extremely excited about the added emphasis on investor communications and relations in the new year,” said Genprex CEO Rodney Varner in a statement. “With the new website and email newsletters we will be launching, we intend to provide to current and potential investors unprecedented insight into what is happening at Genprex as we continue to work at the forefront of the new age of immunogene therapy cancer treatments.”

Based in Austin, Texas, Genprex is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.

In August, Genprex entered into a collaboration with The University of Texas MD Anderson Cancer Center to extend two option agreements between Genprex and MD Anderson pertaining to the use of TUSC2, the active agent in Oncoprex.

The company has also recently hired Jan Stephens, RN, in its Cambridge office as Genprex’s new vice-president of clinical operations. Stephens, who has more than 20 years of clinical experience in the biopharma industry, is being tasked with supporting the various clinical development programs for Oncoprex.

Genprex shares rose 7.7% to $1.26 in Wednesday’s morning trading session.

Quick facts: Genprex, Inc.

Price: 3.66 USD

Market: NASDAQ
Market Cap: $141.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...



Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

2 min read